Potential drug–drug interactions in patients with non-small cell lung cancer at a university hospital in Turkey

Albayrak, Aslınur; Duzenli, Tarik; Kayıkçıoğlu, Erkan

doi:10.1007/s00432-023-04890-0

J Cancer Res Clin Oncol

2023

DOI: 10.1007/s00432-023-04890-0

|View full text |Cite

Potential drug–drug interactions in patients with non-small cell lung cancer at a university hospital in Turkey

Aslınur Albayrak

Tarik Duzenli

Erkan Kayıkçıoğlu

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Potential Drug-Drug Interactions in Outpatient Lung Cancer Patients in a University Hospital

Jafarova Demirkapu,

Cavdar

2024

Pharmacology

View full text Add to dashboard Cite

Introduction: Concomitant use of drugs in the same or different indications can sometimes lead to undesirable interactions. The prevalence of drug interactions is high in cancer patients. In this study, we aimed to determine the frequency and clinical severity of drug interactions in outpatient lung cancer patients. Methods: The drugs used, kidney and liver blood analysis results of 160 outpatient lung cancer patients over the age of 18 who received chemotherapy between October 2020 and July 2021 were evaluated. The Lexi-Interact online database was used to identify the types of clinically significant drug interactions, frequently interacting drugs, and clinical outcomes predicted by the databases. Results: The average number of drugs per patient was 4.2±2.3. It was determined that there was a relationship between multi-drug use and comorbidity, and the number of drugs used increased as the number of diagnoses increased. A relationship was also found between potential drug-drug interactions (pDDI), which we observed in 52.5% of the patients, and the number of drugs used and age. The most common clinically significant C (36.9%), D (16.9%) and X (10.6%) type pDDI were detected between conventional paclitaxel-hydrochlorothiazide, conventional paclitaxel-carboplatin, and ipratropium-tiotropium, respectively. Conclusions: The use of frequently interacting drugs in outpatient lung cancer patients can lead to pDDI. In these patients, the application of therapy by observing the drug-drug interaction may improve the quality of life.

show abstract

Potential Drug-Drug Interactions in Outpatient Lung Cancer Patients in a University Hospital

Jafarova Demirkapu,

Cavdar

2024

Pharmacology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Potential drug–drug interactions in patients with non-small cell lung cancer at a university hospital in Turkey

Cited by 1 publication

References 41 publications

Potential Drug-Drug Interactions in Outpatient Lung Cancer Patients in a University Hospital

Potential Drug-Drug Interactions in Outpatient Lung Cancer Patients in a University Hospital

Contact Info

Product

Resources

About